secwatch.observer — SEC 8-K summary
======================================

Issuer:     Crinetics Pharmaceuticals, Inc. (CRNX)
CIK:        0001658247
Form:       8-K
Filed at:   2023-09-13T23:59:59+00:00
Accession:  0001193125-23-234504
Event type: other_material
Sentiment:  neutral
Materiality: 0.60
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Crinetics upsizes public offering to $350M gross; prices 11.44M shares at $30.59
--------------------------------------------------------------------------------

- Priced upsized offering of 11,441,648 shares at $30.59 per share, expected gross proceeds ~$350M.
- Net proceeds expected ~$328.6M; ~$378M if underwriters' 30-day option for 1.72M additional shares is exercised.
- Proceeds to fund development of paltusotine, CRN04894, and other R&D programs; closing expected Sept 15, 2023.
- Initial announcement on Sept 11 targeted $250M; offering upsized to $350M at pricing on Sept 12.
- J.P. Morgan, Morgan Stanley, Leerink, and Piper Sandler act as joint book-running managers.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1658247/000119312523234504/0001193125-23-234504-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1658247/000119312523234504/d465389d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-234504

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer